No description yet.
New York, NY
1 source · checked 1 time, last 3h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The filing identifies a Form D exempt securities offering but does not state a round label, amount, valuation, investors, or announcement date.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Form D (equity, series a common stock) [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | n/a | 2026-09-17 | not stated | No recent discussion |
1 source · checked 1 time, last 3h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The filing identifies a Form D exempt securities offering but does not state a round label, amount, valuation, investors, or announcement date. [ BUILT WITH ]·[ SEARCH ]from a Form D filing·[ SCRAPE ]1 page read: sec.gov·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
CAD Therapeutics develops Clonicaine™, an investigational drug candidate for people with PTSD that is being studied through a physician-administered sympathetic-block procedure.
Checked against 4 sources today
None named.